Back

The need for urgency in treating hyperlipidemia in post-ACS patients

1 September 2019 (13:05 - 13:15)
Organised by:
Congress Presentation Part of: Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes Treatment ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Francois Schiele

Regional University Hospital Jean Minjoz, Besancon (France)

5 More presentations in this session

Presentation thumbnail
Introduction
Professor J. Jukema (Leiden, NL)
Video
Presentation thumbnail
Enriching the PCSK9i evidence - The most recent analyses from ODYSSEY OUTCOMES
Professor J. Jukema (Leiden, NL)
Presentation thumbnail
Evaluating the benefit/risk and safety profile of PCSK9 inhibitors - Clinical and economic implications
Doctor C. Ballantyne (Houston, US)
Presentation thumbnail
Panel discussion
Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)
Presentation thumbnail
Conclusion and key takeaways
Professor J. Jukema (Leiden, NL) Professor F. Schiele (Besancon, FR) Doctor C. Ballantyne (Houston, US)

Access the full session

Session thumbnail
Evolving scientific evidence with PCSK9 inhibitors based on ODYSSEY outcomes

The Event

Event poster

ESC Congress 2019

1 September 2019 13:05 CET

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources